The FDA has given the nod to Mydayis (mixed salts of a single-entity amphetamine product, Shire), a once-daily treatment consisting of three different types of drug-releasing beads for patients 13 years of age and older with attention-deficit/hyperactivity disorder (ADHD).
Shire has previously suggested the new drug would be its most important 2017 launch and could be worth around $500m a year in peak sales, although consensus analyst estimates a more modest $288m by 2020, mainly because of anticipated payer resistance in the USA as the new drug has the same ingredients as Adderall XR. Shire, Mydayis' manufacturer, stated in a press release that the medication would become available to consumers in the third quarter of 2017.
Shares in the FTSE 100 company rose around 1.5pc in trading as investors digested the news.
"Mydayis is the latest innovation in Shire's 20-year legacy of helping to support the treatment of ADHD". Jefferies analysts noted that every ADHD drug launched by Shire has significantly exceeded initial market projections.
ADHD is characterised by inattention either with or without hyperactivity-impulsivity.
Dr Ornskov said with the approval, Shire hoped to help patients who needed a once-daily treatment option. According to some estimates up to 11% of children in the U.S. are affected and more than half continue to suffer from the disorder in adulthood.
Le climat des affaires au plus haut depuis juillet 2011 — France
Dans le bâtiment, les chefs d'entreprise sont plus nombreux qu'en mai à signaler une augmentation de leur activité passée. Les statisticiens publics revoient aussi à la hausse d'un point les résultats de l'enquête du mois de mai.
With its acquisition of Baxalta past year, Shire has been building a presence in rare diseases, but ADHD is still a major part of its business.
Both Mydayis and Adderall XR contain amphetamine, a stimulant that elevates levels of dopamine - a neurotransmitter associated with motivation, attention and movement.
Mydayis is created to help eliminate the use of short-acting stimulants given to boost the impact of long-acting ones, especially among college students and adults, Mattingly said. Mydayis is not for use in children 12 years and younger. Non-stimulant ADHD treatments have fewer side-effects but are typically less effective.
Shire first filed an application to market Mydayis in 2006 but faced multiple setbacks, including a requirement for additional studies to satisfy the FDA.
Other ADHD drug developers include Neos Theraputics Inc, Alcobra Ltd and Aevi Genomic Medicine.
- Trump Refuses To Join G7 Statement Endorsing Paris Climate Accord
- BNM to provide information to Royal Commission on forex losses
- Trump proposes to build Mexico wall with solar panels
- Mattis Says US And China Agree On North Korean Threat
- SpiceJet signs provisional deal to buy 40 Boeing 737 MAX 10 jets
- Man Utd boss Mourinho refutes tax fraud accusations
- Voice, video calls unblocked in UAE
- Netflix unveils epic new key art for 'Marvel's The Defenders'
- Horrifying footage released showing US cop fatally shooting motorist seven times
- Virginia girl could be in extreme danger